Top

Published in:

01-02-2021 | Hepatitis B | Editorial

Sequential combination therapies for HBeAg-positive chronic hepatitis B: the search continues

Authors: Ankur Jindal, Manoj Kumar

Published in: Hepatology International | Issue 1/2021

Excerpt

Total eradication of the hepatitis B virus (HBV) is still elusive, as even if HBsAg is lost, covalently closed circular DNA (cccDNA) often persists in the hepatocytes. The currently available drugs for treatment of chronic hepatitis B (CHB) are not able to give sustained off-treatment HBsAg loss (functional cure) in most of the patients, which is the ultimate goal of therapy of CHB and is closest to eradication. In the absence of functional cure, Hepatitis B e antigen (HBeAg) seroconversion and undetectable HBV DNA are taken as end-points of antiviral therapy in HBeAg-positive CHB. …

European Association for the Study of the Liver EASL. Clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol 2017;67(2):370–398CrossRef

Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, Gane E, Peginterferon Alfa-2a HBeAg-Positive Chronic Hepatitis B Study Group, et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005;352(26):2682–2695CrossRef

Sonneveld MJ, Hansen BE, Piratvisuth T, Jia J, Zeuzem S, Gane E, et al. Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels. Hepatology 2013;58:872–880CrossRef

Marcellin P, Ahn SH, Ma X, et al. Combination of tenofovir disoproxil fumarate and peginterferon α-2a increases loss of hepatitis B surface antigen in patients with chronic hepatitis B. Gastroenterology 2016;150(134–144):e10

Sarin SK, Sood A, Kumar M, Arora A, Amrapurkar D, Sharma BC, Konar A, National Collaborative Group on Hepatitis B, India, et al. Effect of lowering HBV DNA levels by initial antiviral therapy before adding immunomodulator on treatment of chronic hepatitis B. Am J Gastroenterol 2007;102(1):96–104CrossRef

Ning Q, Han M, Sun Y, et al. Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: a randomized open-label trial (OSST trial). J Hepatol 2014;61:777–784CrossRef

Chi H, Hansen BE, Guo S, et al. Pegylated interferon Alfa-2b Add-on treatment in hepatitis b virus envelope antigen-positive chronic hepatitis b patients treated with nucleos(t)ide analogue: a randomized, controlled trial (PEGON). J Infect Dis 2017;215:1085–1093CrossRef

Xu W, Li Q, Huang C, et al. Efficacy of peg-interferon–nucleoside analog sequential optimization therapy in HBeAg positive patients with CHB. Hepatol Int 2020. https://doi.org/10.1007/s12072-020-10095-1CrossRefPubMedPubMedCentral

Sonneveld MJ, Brouwer WP, van der Meer AJ. Posttreatment hepatitis B surface antigen seroreversion: the bane of combination therapy in chronic hepatitis B? Gastroenterology 2016;150:1254–1255CrossRef

10.

Hu P, Shang J, Zhang W, et al. HBsAg loss with peg-interferon Alfa-2a in hepatitis B patients with partial response to nucleos(t) ide Analog: new switch study. J Clin Transl Hepatol 2018;6:25–34CrossRef

11.

Lampertico P, Viganò M, Di Costanzo GG, Sagnelli E, Fasano M, Di Marco V, et al. Randomised study comparing 48 and 96 weeks peginterferon a-2a therapy in genotype D HBeAg-negative chronic hepatitis B. Gut 2013;62:290–298CrossRef

12.

Chen X, Chen X, Chen W, Ma X, Huang J, Chen R. Extended peginterferon alfa-2a (Pegasys) therapy in Chinese patients with HBeAg-negative chronic hepatitis B. J Med Virol 2014;86:1705–1713CrossRef

13.

Marcellin P, Ahn SH, Ma X, Caruntu FA, Tak WY, Elkashab M, et al. Combination of tenofovir disoproxil fumarate and peginterferon a-2a increases loss of hepatitis B surface antigen in patients with chronic hepatitis B. Gastroenterology 2016;150:134–144CrossRef

Title: Sequential combination therapies for HBeAg-positive chronic hepatitis B: the search continues
Authors: Ankur Jindal
Manoj Kumar
Publication date: 01-02-2021
Publisher: Springer India
Keyword: Hepatitis B
Published in: Hepatology International / Issue 1/2021
Print ISSN: 1936-0533
Electronic ISSN: 1936-0541
DOI: https://doi.org/10.1007/s12072-020-10129-8

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Sequential combination therapies for HBeAg-positive chronic hepatitis B: the search continues

Excerpt

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2021

One-year Fibrosis-4 index helps identify minimal HCC risk in non-cirrhotic chronic hepatitis B patients with antiviral treatment

How can we reduce the impact of COVID-19 pandemic on timely access to liver transplantation in children?

Efficacy of peg-interferon–nucleoside analog sequential optimization therapy in HBeAg-positive patients with CHB

Dipeptidyl peptidase-4 inhibitors may accelerate cirrhosis decompensation in patients with diabetes and liver cirrhosis: a nationwide population-based cohort study in Taiwan

Regression of portal hypertension: underlying mechanisms and therapeutic strategies

Management of primary sclerosing cholangitis and its complications: an algorithmic approach

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page